title: The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism.
abstract: Venous thromboembolism, which is manifested as deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant cause of death, disability, and discomfort. Two million people/year are affected by VTE, making it the third most common cardiovascular disease after coronary heart disease and stroke. The rationale for VTE prophylaxis stems from the clinically silent presentation of the disease and its prevalence among hospitalized patients. At greatest risk are patients undergoing major orthopedic surgery and those admitted to the intensive care unit with acute myocardial infarction, heart failure, ischemic stroke, respiratory disease, systemic infection, or other medical conditions that immobilize patients for 5 days or longer. Several anticoagulant regimens have been effective in reducing the risk of VTE after major orthopedic surgery. For patients undergoing total hip or knee replacement, treatment with adjusted-dose warfarin, low-molecular-weight heparins, or fondaparinux may be used. Warfarin, which has been around for more than 50 years, is the only oral anticoagulant available for VTE prophylaxis. Ximelagatran, a new low-molecular-weight oral prodrug of the direct thrombin inhibitor melagatran, has advantages over warfarin that may make it the drug of choice for prevention of VTE.
authors.affiliation: Mercer University Southern School of Pharmacy, Atlanta, Georgia 30341, USA.
authors.forename: David
authors.initials: D
authors.lastname: Hawkins
mesh_terms: D000284:Administration, Oral; D001384:Azetidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D001596:Benzylamines; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D013917:Thrombin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; C426686:ximelagatran; D013917:Thrombin